Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 31Lymphoma 18Lymphoma, Large B-Cell, Diffuse 17Sarcoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasm Metastasis 10Hodgkin Disease 9Lymphoma, Non-Hodgkin 8Recurrence 7Prostatic Neoplasms 7Neoplasms 7Multiple Myeloma 7Burkitt Lymphoma 7Ovarian Neoplasms 6Leukemia 6Lymphoma, B-Cell 5Fallopian Tube Neoplasms 5Cardiotoxicity 5Carcinoma, Hepatocellular 5Urinary Bladder Neoplasms 4Osteosarcoma 4Liver Neoplasms 4Triple Negative Breast Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 3Colonic Neoplasms 3Waldenstrom Macroglobulinemia 2

Interventions

Paclitaxel 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Endometrial Cancer × Doxorubicin × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡